The launch of our Process & Analytical Development and Manufacturing Facility marks a strategic resurgence in the Boston area, as we consolidate and fortify our presence in the region with a renewed focus on our expertise in process & analytical development (PAD) and a pathway to commercial drug substance manufacturing, all within a single location.
With our emphasis on biologics, vaccines, nucleic acids, and gene therapy, the Boston facility is set to become a center of innovation. The site is now a commercially licensed facility offering process and analytical development (PAD) and 10x 2,000L drug substance (DS) manufacturing capacity. By merging our technical capabilities with manufacturing, we are enhancing our ability to deliver life-changing therapies to patients more swiftly and efficiently.
As we embark on this new chapter, our commitment to excellence remains unwavering. We're excited about the opportunities ahead and look forward to continued growth and success in Boston. Cheers to our dedicated team and the bright future we're building together!
Learn more about our Boston facility by downloading our fact sheet:
%201.png)
